Company profile

Ticker
BIIB
Exchange
Website
CEO
Michel Vounatsos
Employees
Incorporated
Location
Fiscal year end
Former names
BIOGEN IDEC INC, BIOGEN IDEC INC., IDEC PHARMACEUTICALS CORP / CA, IDEC PHARMACEUTICALS CORP / DE
SEC CIK
IRS number
330112644

BIIB stock data

(
)

Calendar

21 Oct 20
1 Dec 20
31 Dec 20

News

Quarter (USD) Sep 20 Jun 20 Mar 20 Sep 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Biogen earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
4 Nov 20 Alfred Sandrock Common Stock Sell Dispose S Yes 350 1,500 525K 13,066.21
1 Sep 20 Mcdonnell Michael R RSU Common Stock Grant Aquire A No 0 16,090 0 16,090
1 Sep 20 Mcdonnell Michael R RSU Common Stock Grant Aquire A No 0 8,045 0 8,045
31 Jul 20 Ginger Gregory Common Stock Payment of exercise Dispose F No 274.69 95 26.1K 4,691.36
31 Jul 20 Ginger Gregory Common Stock Option exercise Aquire M No 0 212 0 4,786.36
31 Jul 20 Ginger Gregory Common Stock Payment of exercise Dispose F No 274.69 128 35.16K 4,574.36
31 Jul 20 Ginger Gregory RSU Common Stock Other Dispose J No 0 216 0 0
31 Jul 20 Ginger Gregory RSU Common Stock Option exercise Dispose M No 0 212 0 216
83.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 999 1006 -0.7%
Opened positions 98 94 +4.3%
Closed positions 105 141 -25.5%
Increased positions 297 319 -6.9%
Reduced positions 403 413 -2.4%
13F shares
Current Prev Q Change
Total value 37.07B 35.53B +4.3%
Total shares 128.49M 132.85M -3.3%
Total puts 4.6M 4.57M +0.7%
Total calls 3.75M 2.56M +46.1%
Total put/call ratio 1.2 1.8 -31.1%
Largest owners
Shares Value Change
Primecap Management 15.7M $4.45B +0.4%
BLK Blackrock 14.46M $4.1B -0.9%
Vanguard 12.35M $3.5B -4.1%
STT State Street 7.52M $2.13B -4.0%
Wellington Management 4.86M $1.38B +1.7%
Clearbridge Advisors 4.02M $1.14B -1.6%
Renaissance Technologies 3.82M $1.08B -2.3%
Geode Capital Management 2.89M $818.54M -4.9%
NTRS Northern Trust 2.38M $676.06M -2.2%
BK Bank Of New York Mellon 2.31M $655.7M -0.3%
Largest transactions
Shares Bought/sold Change
Nordea Investment Management Ab 520.37K -566.82K -52.1%
Vanguard 12.35M -528.04K -4.1%
D. E. Shaw & Co. 367.89K -475.81K -56.4%
GS Goldman Sachs 886.38K -451.26K -33.7%
Amundi Pioneer Asset Management 503.46K -416.53K -45.3%
Arrowstreet Capital, Limited Partnership 298.31K -412.29K -58.0%
MS Morgan Stanley 693.4K +316.68K +84.1%
Ajo 106.44K -316.65K -74.8%
Avidity Partners Management 315.1K +315.1K NEW
STT State Street 7.52M -313.18K -4.0%

Financial report summary

?
Risks
  • If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed.
  • The ongoing COVID-19 pandemic may, directly or indirectly, adversely affect our business, results of operations and financial condition.
  • Our long-term success depends upon the successful development of new products and additional indications for existing products.
  • If we fail to compete effectively, our business and market position would suffer.
  • Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives.
  • Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.
  • Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied.
  • Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.
  • Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to obtain and maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, reputation, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.
  • A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.
  • We depend on relationships with collaborators, joint venture partners and other third parties for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.
  • Our results of operations may be adversely affected by current and potential future healthcare reforms.
  • Management and key personnel changes may disrupt our operations, and we may have difficulty retaining key personnel or attracting and retaining qualified replacements on a timely basis for management and other key personnel who may leave the Company.
  • If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.
  • Our sales and operations are subject to the risks of doing business internationally.
  • We are building a large-scale biologics manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.
  • Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenues.
  • Our success in commercializing biosimilars developed by Samsung Bioepis is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If Samsung Bioepis is unsuccessful in the development, manufacture and commercialization of biosimilars, we may not realize the anticipated benefits of our investment in Samsung Bioepis.
  • Our operating results are subject to significant fluctuations.
  • Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.
  • Our investments in properties may not be fully realized.
  • Our portfolio of marketable securities is subject to market, interest and credit risk that may reduce its value.
  • There can be no assurance that we will continue to repurchase shares or that we will repurchase shares at favorable prices.
  • We may not be able to access the capital and credit markets on terms that are favorable to us.
  • Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business.
  • Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.
  • The illegal distribution and sale by third parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.
  • The increasing use of social media platforms presents new risks and challenges.
  • Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Abeta, argument, banc, Climate, deeply, Denali, en, entrant, estoppel, fossil, Healthy, panel, postponed, Priority, Prolonged, ranibizumab, rehearing, reluctance, renowned, repeat, Sun, SZE, TV, Vehicle
Removed: AD, circulation, compound, copy, Cosmetic, improved, improvement, ordered

Patents

GRANT
Utility
Methods for treating Alzheimer's disease
24 Nov 20
A method for treatment of a human patient for Alzheimer's disease (AD) comprises sequentially administering multiple doses of a recombinant, fully human, anti-amyloid beta monoclonal antibody to the patient.
APP
Utility
Process for Preparing Spiro Derivatives
15 Oct 20
The invention relates to a novel process for preparing Spiro derivatives, in particular 7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one, and to novel intermediates for use in said process along with processes for preparing said intermediates.
APP
Utility
Methods for Treating Alzheimer's Disease
1 Oct 20
Provided are methods for treating Alzheimer's disease in a human subject in need thereof when the subject develops an Amyloid Related Imaging Abnormality (ARIA) during a treatment regimen comprising administration of multiple doses of an anti-beta-amyloid antibody (e.g., BIIB037) to the subject.
GRANT
Utility
Methods of intravenous administration of glyburide
29 Sep 20
The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 μg/hr and about 300 μg/hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours.
GRANT
Utility
Composition containing glibenclamide
1 Sep 20
NSC antagonists are disclosed as useful in the treatment of dementia, in delaying the onset of dementia, and in the prevention of dementia.